|
Volumn 16, Issue 11, 2010, Pages 1194-1195
|
Inside the microbial and immune labyrinth: Totally gutted
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ADALIMUMAB;
AZATHIOPRINE;
CERTOLIZUMAB PEGOL;
CYTOKINE;
CYTOKINE ANTIBODY;
FONTOLUZIMAB;
GAMMA INTERFERON;
GAMMA INTERFERON ANTIBODY;
INFLIXIMAB;
INTERLEUKIN 1;
INTERLEUKIN 12;
INTERLEUKIN 12 ANTIBODY;
INTERLEUKIN 15;
INTERLEUKIN 17;
INTERLEUKIN 18;
INTERLEUKIN 1BETA;
INTERLEUKIN 21;
INTERLEUKIN 23;
INTERLEUKIN 23 ANTIBODY;
INTERLEUKIN 27;
INTERLEUKIN 6;
INTERLEUKIN 7;
PLACEBO;
STAT4 PROTEIN;
STEROID;
TRANSCRIPTION FACTOR;
TUMOR NECROSIS FACTOR ALPHA;
TUMOR NECROSIS FACTOR ALPHA ANTIBODY;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
USTEKINUMAB;
CLINICAL TRIAL;
COLITIS;
CROHN DISEASE;
CYTOKINE PRODUCTION;
DRUG EFFICACY;
DRUG RESPONSE;
DRUG TREATMENT FAILURE;
ENTERITIS;
GENE OVEREXPRESSION;
HUMAN;
IMMUNOREGULATION;
INTESTINE FLORA;
INTESTINE WALL;
LYMPHOCYTE ACTIVATION;
NONHUMAN;
PRIORITY JOURNAL;
RECURRENT DISEASE;
SHORT SURVEY;
SINGLE DRUG DOSE;
TH1 CELL;
ANIMALS;
ANTIBODIES, MONOCLONAL;
CLINICAL TRIALS AS TOPIC;
CROHN DISEASE;
GASTROINTESTINAL TRACT;
HUMANS;
MODELS, BIOLOGICAL;
TRANSLATIONAL RESEARCH;
|
EID: 78149341767
PISSN: 10788956
EISSN: 1546170X
Source Type: Journal
DOI: 10.1038/nm1110-1194 Document Type: Short Survey |
Times cited : (20)
|
References (12)
|